Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00402506
Other study ID # 06004
Secondary ID
Status Completed
Phase Phase 3
First received November 20, 2006
Last updated November 15, 2007
Start date November 2006
Est. completion date September 2007

Study information

Verified date November 2007
Source Medicure
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationCanada: Health CanadaGermany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG) surgery compared with placebo.


Description:

Coronary artery bypass grafting (CABG) effectively relieves angina, results in longer survival, and a better quality of life in specific subgroups of patients with obstructive coronary artery disease. Due to the high incidence of coronary artery disease worldwide, as well as the effectiveness of the surgical procedure, CABG surgery makes up one of the top ten most frequently performed procedures in North America and Europe. In the United States it is estimated that approximately 467,000 CABG procedures were performed in 2003.

Despite the benefits of CABG surgery, patients undergoing these procedures may also suffer serious adverse outcomes including operative mortality, myocardial infarction, unstable angina, ventricular failure, life-threatening arrhythmia, renal insufficiency, and stroke. Some of the proposed causes of cardiovascular morbidity and mortality after CABG include perioperative ischemia, inadequate myocardial protection and reperfusion injury. The impact of these serious complications is significant. Incidence rates of death and MI following CABG surgery range from 5% to 12% depending on risk status. Results from large clinical trials have recently demonstrated the importance of neurologic deficits as a problematic outcome of CABG. These deficits include memory impairment, psychomotor, visuospatial, attention and language abilities as measured by neuropsychological testing as well as sensorimotor abnormalities associated with stroke.

MC-1 is a naturally occurring metabolite of vitamin B6. Evidence from pre-clinical and clinical studies suggests that MC-1 protects the heart from ischemic damage and ischemia-reperfusion injury. This trial will assess the cardioprotective effects of MC-1 compared to placebo in patients undergoing high-risk CABG surgery.


Recruitment information / eligibility

Status Completed
Enrollment 3000
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must be scheduled to undergo CABG surgery (during routine scheduling times) and had planned to use cardiopulmonary bypass.

- Provide informed consent

- Age = 18

- Male patients, or female patients not of childbearing potential or who have had a negative pregnancy test and are practicing adequate contraception

- Patients must be considered at high risk for subsequent myocardial complications defined as meeting 2 or more of the following:

- Age = 65

- Current or recent smoker (within last 6 months)

- History of diabetes mellitus requiring treatment other than diet

- Evidence of left ventricular dysfunction or congestive heart failure assessed by:

- Ejection fraction (EF) = 45%

- Left ventricular end diastolic pressure (LVEDP) or pulmonary wedge pressure (PWP) = 20 mm Hg

- Pulmonary edema by chest X-ray

- Cardiothoracic ratio > 50% on chest X-ray

- History of a previous non-disabling stroke, transient ischemic attack, or carotid endarterectomy

- Urgent CABG intervention defined as the need to stay in the hospital (although patient may be operated on within a normal scheduling routine)

- History of a myocardial infarction that occurred more than 48 hours but less than 6 weeks prior to CABG surgery

- Prior peripheral artery surgery or angioplasty

- Moderate renal dysfunction defined as creatinine clearance = 30 ml/min, but < 60 ml/min

- Presence of at least one asymptomatic carotid artery stenosis (= 50%) either in one or two carotid arteries

Exclusion Criteria:

- Planned associated valve surgery or concurrent carotid endarterectomy

- Planned aortic dissection repair or aortic root reconstruction

- Screening visit occurring less than 4 hours before scheduled CABG surgery

- Mini-Mental State Examination (MMSE) score less than 24 at the screening visit

- Current cardiogenic shock, acute left ventricular rupture, ventricular septal rupture, or papillary muscle rupture

- Uncontrolled diabetes defined as fasting serum blood glucose value equal to or greater than 24 mmol/L (432 mg/dl) at the time of screening (if fasting serum blood glucose not obtained at screening, values obtained within 30 days prior to screening visit may be used)

- Myocardial infarction occurring < 48 hours prior to planned CABG surgery

- Severe renal dysfunction defined as an estimated creatinine clearance value of < 30 ml/min or nephrotic syndrome at screening (or measured creatinine clearance value obtained within 30 days prior to screening visit)

- History of liver cirrhosis, chronic active hepatitis (known positive serum test within 6 months of enrolment), or severe liver dysfunction; or liver transaminase = 3 times upper limit of normal (ULN) at screening (or obtained within 30 days prior to screening visit).

- History of malignancy during last 5 years except for basal cell carcinoma

- Planned surgery for atrial fibrillation

- Planned associated transmyocardial revascularization

- Planned associated ventricular remodeling

- Pregnancy or potential for pregnancy

- Any medical or psychiatric condition which, in the opinion of the investigator, makes the patient an unsuitable candidate for the study

- Significant, ongoing alcohol or drug abuse

- Participation in any other investigational drug or device study within 30 days of randomization

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
(MC-1) Pyridoxal 5'-phosphate


Locations

Country Name City State
Canada Montreal Heart Institute Montreal Quebec
United States Duke Clinical Research Institute Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medicure

Countries where clinical trial is conducted

United States,  Canada, 

References & Publications (1)

Kandzari DE, Labinaz M, Cantor WJ, Madan M, Gallup DS, Hasselblad V, Joseph D, Allen A, Green C, Hidinger KG, Krucoff MW, Christenson RH, Harrington RA, Tcheng JE. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol. 2003 Sep 15;92(6):660-4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary combined incidence of cardiovascular death or nonfatal myocardial infarction on days up to and including post-operative day (POD) 30
Secondary length of hospital stay for index hospitalization
Secondary length of stay in intensive care unit (ICU) or coronary care unit (CCU) for index hospitalization
Secondary incidence of cardiovascular death up to and including POD 90
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Completed NCT02707445 - Genotyping Influences Outcome of Coronary Artery Stenting N/A